Delta 9 Reports Financials for Q3 2022
15 Novembro 2022 - 1:05AM
DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the
“Company”), is pleased to announce financial and operating results
for the three-month and nine-month period ending September 30,
2022.
Financial Highlights for the three-month
period ending September 30, 2022
-
Net revenue of $15.7 million for the third quarter of 2022, an
increase of 3%, from $15.2 million for the same quarter last
year.
-
Gross profit of $1.9 million for the third quarter of 2022, versus
$4.8 million for the same quarter last year.
-
Net income (loss) from operations of $(6.2) million for the third
quarter of 2022 versus a net income (loss) from operations of
$(55,031) for the same quarter last year.
-
Adjusted EBITDA (loss) of $(1.7) million for the third quarter of
2022 versus an adjusted EBITDA of $191,056 for the same quarter
last year.
Financial Highlights for the nine-month
period ending September 30, 2022
-
Net revenue of $45.7 million for the first nine months of 2022, an
increase of 1%, from $45.2 million for the same period last
year.
-
Gross profit of $9.5 million for the first nine months of 2022,
versus $13.4 million for the same period last year.
-
Net income (loss) from operations of $(12.6) million for the first
nine months of 2022 versus a net income (loss) from operations of
$(4.1) million for the same period last year.
-
Adjusted EBITDA (loss) of $(3.8) million for the first nine months
of 2022 versus an adjusted EBITDA of $1.4 million for the same
period last year.
“In the third quarter of 2022 we have seen a
degree of seasonality and timing issues relating to provincial
government’s purchasing patterns affecting our wholesale business
and B2B businesses and impacting sequential revenue growth,” said
John Arbuthnot, CEO of Delta 9. “The Canadian cannabis industry
continues to struggle with intense competition resulting in margin
compression and affecting overall growth. We remain confident that
Delta 9 will be able to navigate the industry challenges and return
the Company to growth and profitability in the coming
quarters.”
3nd Quarter
Operational Highlights
- Delta 9 announced
that it has received a Cannabis Distributor License from the Liquor
Gaming and Cannabis Authority (the “LGCA”) of Manitoba, making the
Company the first licensed distributor of cannabis products in the
province. Under the License, Delta 9 is authorized to acquire,
store, sell and deliver cannabis in accordance with The Liquor,
Gaming and Cannabis Control Act. The Company’s distribution
services will allow out-of-province suppliers to improve logistics
efficiencies and reduce shipping costs into the Manitoba market and
will provide Delta 9 with additional diversified revenue
streams.
- Delta 9 placed 64th
on the 2022 Globe and Mail’s Report on Business ranking of Canada’s
Top Growing Companies out of the 430 companies that participated.
Based on a three-year revenue growth rate, Delta 9 Cannabis grew
720%, from $7.6 million in 2018 to $62.3 million in 2021.
- Delta 9 announced
that it has purchased Garden Variety’s three branded retail
cannabis stores located in Manitoba for $3.25 million in common
shares of Delta 9. The Company expects the transaction to be
accretive in 2022 and 2023 before synergies. The acquisition
represents an attractive revenue multiple of approximately 0.41x
annualized revenue. The combination of the Garden Variety cannabis
stores and Delta 9’s existing store network will make Delta 9 a
leading retailer of cannabis products in Canada with 38
stores.
- Delta 9 announced
the cash repayment of its unsecured 8.5% convertible debentures
issued in July. The $11.8 million cash repayment
represents a full payout of the Convertible Debentures. The
Convertible Debentures were previously traded on the Toronto Stock
Exchange under the trading symbol “DN.DB”. The Company met the
pre-disbursement conditions required to draw-down $11.8
million under its credit facility with ConnectFirst Credit
Union and concurrently made the cash repayment of the Convertible
Debentures. The Company's $11.8 million draw-down from
its credit facility is subject to a 60-month term at a fixed rate
of 4.55% per annum, amortized over 144 months.
Summary of Quarterly Results:
Consolidated Statement of Net Income (Loss) |
Q4 2021 |
Q1 2022 |
Q2 2022 |
Q3 2022 |
Revenue |
$17,120,932 |
$12,479,577 |
$17,495,078 |
$15,693,969 |
Cost of Sales |
12,247,951 |
9,515,096 |
12,850,777 |
13,772,202 |
Gross Profit Before Unrealized Gain From Changes In Biological
Assets |
4,872,981 |
2,964,481 |
4,644,301 |
1,921,767 |
Unrealized gain from changes in fair value of biological assets
(Net) |
(1,853,245) |
874,293 |
(542,188) |
340,602 |
Gross Profit |
$3,019,736 |
$3,838,774 |
$4,102,113 |
$2,262,369 |
|
|
|
|
|
Expenses |
|
|
|
|
General and Administrative |
2,972,633 |
3,810,316 |
4,043,257 |
3,668,708 |
Sales and Marketing |
3,212,250 |
2,713,630 |
3,381,223 |
3,710,471 |
Share Based Compensation |
371,433 |
246,944 |
107,121 |
1,086,858 |
Total Operating Expenses |
$6,556,316 |
$6,770,890 |
$7,531,601 |
$8,466,037 |
|
|
|
|
|
Adjusted EBITDA (Loss) 1 |
613,562 |
(1,694,529) |
(391,054) |
(1,683,018) |
Income (Loss) from Operations |
$(3,536,580) |
$(2,932,116) |
$(3,429,488) |
$(6,203,668) |
Other Income/ Expenses |
(1,622,996) |
(1,189,730) |
(1,402,588) |
(1,470,942) |
Net Income (Loss) |
$(5,159,576) |
$(4,121,846) |
$(4,832,076) |
$(7,674,610) |
Basic and Diluted Earnings (Loss) Per Share |
$(0.05) |
$(0.04) |
$(0.04) |
$(0.06) |
-
Adjusted EBITDA is a non-IFRS measure, and is calculated as
earnings before interest, tax, depreciation and amortization,
share-based compensation expense, fair value changes and other
non-cash items.
A comprehensive discussion of Delta 9’s
financial position and results of operations is provided in the
Company’s Management Discussion & Analysis for the three-month
and nine-month period ending September 30, 2022 filed on SEDAR on
November 14, 2022 and can be found at www.sedar.com.
2022 Third Quarter Results Conference
Call
A conference call to discuss the above results
is scheduled for November 15, 2022. The conference call will be
hosted that day at 10:00 a.m. Eastern Time by John Arbuthnot, Chief
Executive Officer, and Jim Lawson, Chief Financial Officer,
followed by a question-and-answer period.
DATE: |
November 15, 2022 |
TIME: |
10:00 am Eastern Time |
Dial in # |
1-888-886-7786 |
REPLAY: |
1-877-674-6060Available until
12:00 midnight Eastern Time, December 15, 2022 |
Replay passcode: |
046070 # |
For more information contact:
Investor & Media Contact:Ian Chadsey VP Corporate
AffairsMobile: 204-898-7722E-mail: ian.chadsey@delta9.ca
About Delta 9 Cannabis Inc.
Delta 9 Cannabis Inc. is a vertically integrated
cannabis company focused on bringing the highest quality cannabis
products to market. The company sells cannabis products through its
wholesale and retail sales channels and sells its cannabis grow
pods to other businesses. Delta 9's wholly-owned subsidiary, Delta
9 Bio-Tech Inc., is a licensed producer of medical and recreational
cannabis and operates an 80,000 square foot production facility
in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a
chain of retail stores under the Delta 9 Cannabis Store brand.
Delta 9's shares trade on the Toronto Stock Exchange under the
symbol "DN" and on the OTCQX under the symbol "DLTNF". For more
information, please visit www.delta9.ca.
Disclaimer for Forward-Looking Information
Certain statements in this release are
forward-looking statements, which reflect the expectations of
management regarding the Company’s future business plans and other
matters. Forward-looking statements consist of statements that are
not purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Forward
looking statements in this news release include statements relating
to: (i) the Company’s plans to establish cannabis distribution
operations in Manitoba; and (ii) the Company’s plans to continue to
expand its retail operations in Canada. Such statements are subject
to risks and uncertainties that may cause actual results,
performance or developments to differ materially from those
contained in the statements, including all risk factors set forth
in the annual information form of Delta 9 dated March 30,
2022 which has been filed on SEDAR. No assurance can be given
that any of the events anticipated by the forward-looking
statements will occur or, if they do occur, what benefits the
Company will obtain from them. Readers are urged to consider these
factors carefully in evaluating the forward-looking statements
contained in this news release and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in
their entirety by these cautionary statements. These
forward-looking statements are made as of the date hereof and the
Company disclaims any intent or obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or results or otherwise, except as required by
applicable securities laws.
Delta 9 Cannabis (TSX:DN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Delta 9 Cannabis (TSX:DN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024